Literature DB >> 11477534

Fulminant leptospirosis in a patient with human immunodeficiency virus infection: case report and review of the literature.

S Jones1, T Kim.   

Abstract

We report a case of fulminant leptospirosis that was acquired in New York City by a patient with underlying infection with human immunodeficiency virus (HIV). Review of the literature on leptospirosis in HIV-infected persons showed that all patients were severely ill but responded well to treatment, which highlights the importance of recognizing this potentially life-threatening illness, especially in unusual settings.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477534     DOI: 10.1086/322645

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

1.  Mild, self-resolving acute leptospirosis in an HIV-infected patient in the Peruvian Amazon.

Authors:  Christian A Ganoza; Eddy R Segura; Mark A Swancutt; Eduardo Gotuzzo; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2005-07       Impact factor: 2.345

Review 2.  Severe course of Lyme neuroborreliosis in an HIV-1 positive patient; case report and review of the literature.

Authors:  Nathalie D van Burgel; Mayke Oosterloo; Frank P Kroon; Alje P van Dam
Journal:  BMC Neurol       Date:  2010-11-30       Impact factor: 2.474

3.  Leptospirosis and human immunodeficiency virus co-infection among febrile inpatients in northern Tanzania.

Authors:  Holly M Biggs; Renee L Galloway; Duy M Bui; Annie B Morrissey; Venance P Maro; John A Crump
Journal:  Vector Borne Zoonotic Dis       Date:  2013-05-10       Impact factor: 2.133

4.  Weil's Disease in an HIV-Infected Patient.

Authors:  Duc B Nguyen; Swethapriya Chaparala; Laurent Morel; Yolin Bueno; Roger D Lovell
Journal:  Cureus       Date:  2021-04-01

5.  Reemerging leptospirosis, California.

Authors:  Elissa Meites; Michele T Jay; Stanley Deresinski; Wun-Ju Shieh; Sherif R Zaki; Lucy Tompkins; D Scott Smith
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.